Artículos de revistas
Melatonin may curtail the metabolic syndrome: studies on initial and fully established fructose-induced metabolic syndrome in rats
Fecha
2013-01Registro en:
Cardinali, Daniel Pedro; Scacchi Bernasconi, Pablo Antonio; Reynoso, Roxana María; Reyes Toso, Carlos Felipe; Scacchi, Pablo; Melatonin may curtail the metabolic syndrome: studies on initial and fully established fructose-induced metabolic syndrome in rats; Molecular Diversity Preservation International; International Journal of Molecular Sciences; 14; 2; 1-2013; 2502-2514
1422-0067
CONICET Digital
CONICET
Autor
Cardinali, Daniel Pedro
Scacchi Bernasconi, Pablo Antonio
Reynoso, Roxana María
Reyes Toso, Carlos Felipe
Scacchi, Pablo
Resumen
To examine the effect of melatonin given to rats simultaneously with fructose on initial and fully developed metabolic syndrome, male Wistar rats had free access to chow and 5% or 10% fructose drinking solution for 8 weeks. As compared to controls, systolic blood pressure augmented significantly under both treatments whereas excessive body weight was seen in rats receiving the 10% fructose only. Rats drinking 5% fructose showed a greater tolerance to a glucose load while rats having access to a 10% fructose drinking solution exhibited the expected impaired glucose tolerance found in the metabolic syndrome. Circulating triglyceride and low density lipoproteins-cholesterol (LDL-c) concentration augmented significantly in rats showing a fully developed metabolic syndrome only, while high blood cholesterol levels were found at both stages examined. Melatonin (25 μg/mL drinking solution) counteracted the changes in body weight and systolic blood pressure found in rats administered with fructose. Melatonin decreased the abnormal hyperglycemia seen after a glucose load in 10% fructose-treated rats but it did not modify the greater tolerance to glucose observed in animals drinking 5% fructose. Melatonin also counteracted the changes in plasma LDL-c, triglyceride and cholesterol levels and decreased plasma uric acid levels. The results underline a possible therapeutical role of melatonin in the metabolic syndrome, both at initial and established phases.